Replimune Group, Inc. (REPL)
| Market Cap | 733.24M +1.5% |
| Revenue (ttm) | n/a |
| Net Income | -314.85M |
| EPS | -3.44 |
| Shares Out | 82.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,972,916 |
| Open | 8.62 |
| Previous Close | 8.62 |
| Day's Range | 8.56 - 9.27 |
| 52-Week Range | 1.50 - 13.24 |
| Beta | 0.91 |
| Analysts | Sell |
| Price Target | 4.67 (-47.41%) |
| Earnings Date | Jun 26, 2026 |
About REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for REPL stock is "Sell." The 12-month stock price target is $4.67, which is a decrease of -47.41% from the latest price.
News
Replimune Group trading resumes
09:35 EDT Replimune (REPL) Group trading resumes
Replimune Group trading halted, volatility trading pause
09:30 EDT Replimune (REPL) Group trading halted, volatility trading pause
Replimune price target raised to $6 from $2 at Wedbush
Wedbush raised the firm’s price target on Replimune (REPL) to $6 from $2 and keeps a Neutral rating on the shares. The firm notes the company announced resubmission and reconsideration…
Replimune presents final first-in-human data for RP2 alone, with nivolumab
Replimune (REPL) Group presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society…
Replimune presents 3-year overall survival data from IGNYTE trial
Replimune (REPL) Group presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the…
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presen...
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presen...
How Replimune's drug got a third chance after the White House intervened
Replimune representatives met with White House officials in early May and by the end of month, the Food and Drug Administration was planning to review the melanoma medication again.
Replimune upgraded to Neutral at JPMorgan with RP1 ‘back on the table’
As previously reported, JPMorgan analyst Anupam Rama upgraded Replimune (REPL) to Neutral from Underweight and established an $8 price target after the FDA and the company agreed on a path…
Replimune upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded Replimune (REPL) to Neutral from Underweight with an $8 price target
Why Penny Stock Replimune (REPL) Nearly Doubled Today
Shares of Replimune ($REPL) are surging today after the biotech company announced that it plans to resubmit its melanoma drug RP1 for FDA approval after the treatment was rejected twice…
Replimune to resubmit RP1 BLA following communications with FDA
Replimune (REPL) announced that following communications with the FDA, the company and the FDA have aligned on a path forward for resubmission and reconsideration of the biologics license application,...
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Replimune said it plans to resubmit its melanoma drug for approval following two earlier rejections. The move follows the departure of Food and Drug Administration Commissioner Marty Makary.
Replimune reaches agreement with US FDA to resubmit melanoma drug application
Replimune said on Friday it it has reached an agreement with the U.S. Food and Drug Administration to resubmit the marketing application for its experimental skin cancer drug after the re...
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announ...
Replimune Gets Third Try at FDA Approval After Makary Departure
Experimental melanoma drug was rejected twice because the Food and Drug Administration questioned its study design.
Replimune jumps on news FDA chief behind RP1 rejection may be removed
Shares of Replimune (REPL) are trading higher on Friday after The Wall Street Journal reported that President Trump has signed off on a plan to fire the Food and Drug…
FDA Commissioner Makary defends agency's decision on Replimune's drug
U.S. Food and Drug Administration Commissioner Dr. Marty Makary on Tuesday defended the agency's decision to not approve Replimune's drug for advanced skin cancer.
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection
Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had nothing to do with the U.S. FDA's decision to not approve Replimune's drug for advanced skin cancer, saying it w...
Replimune rises after Wall Street Journal editorial defending RP1
In an opinion article, The Wall Street Journal’s The Editorial Board argued that the Food and Drug Administration’s rejection of Replimune’s (REPL) RP1 melanoma therapy contradicts both expert opinion...
Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'
Philip Astley-Sparke, executive chairman and co-founder at Replimune, joins ‘Squawk on the Street' to discuss the company's next steps after the FDA denied its melanoma drug.
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno...
US FDA declines to approve Replimune's drug for advanced skin cancer
The U.S. Food and Drug Administration on Friday declined to approve Replimune's drug for advanced skin cancer, the regulator said.
Replimune Group Transcript: Leerink Global Healthcare Conference 2026
The company is preparing for an April 10th PDUFA for its lead asset RP1 in advanced melanoma, with strong physician and patient advocacy support and commercial readiness in place. RP2 and additional indications are advancing, with key data expected by early next year. Cash runway extends into early 2027.
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno...